全文获取类型
收费全文 | 3940篇 |
免费 | 393篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 103篇 |
妇产科学 | 104篇 |
基础医学 | 500篇 |
口腔科学 | 84篇 |
临床医学 | 447篇 |
内科学 | 911篇 |
皮肤病学 | 25篇 |
神经病学 | 319篇 |
特种医学 | 112篇 |
外科学 | 355篇 |
综合类 | 164篇 |
一般理论 | 8篇 |
预防医学 | 482篇 |
眼科学 | 38篇 |
药学 | 349篇 |
中国医学 | 8篇 |
肿瘤学 | 293篇 |
出版年
2021年 | 63篇 |
2020年 | 46篇 |
2019年 | 65篇 |
2018年 | 74篇 |
2017年 | 41篇 |
2016年 | 47篇 |
2015年 | 61篇 |
2014年 | 88篇 |
2013年 | 138篇 |
2012年 | 174篇 |
2011年 | 215篇 |
2010年 | 87篇 |
2009年 | 97篇 |
2008年 | 170篇 |
2007年 | 204篇 |
2006年 | 199篇 |
2005年 | 206篇 |
2004年 | 195篇 |
2003年 | 170篇 |
2002年 | 202篇 |
2001年 | 148篇 |
2000年 | 139篇 |
1999年 | 125篇 |
1998年 | 42篇 |
1997年 | 39篇 |
1996年 | 28篇 |
1995年 | 45篇 |
1994年 | 27篇 |
1992年 | 66篇 |
1991年 | 90篇 |
1990年 | 51篇 |
1989年 | 78篇 |
1988年 | 80篇 |
1987年 | 86篇 |
1986年 | 58篇 |
1985年 | 67篇 |
1984年 | 50篇 |
1983年 | 32篇 |
1982年 | 26篇 |
1979年 | 41篇 |
1978年 | 23篇 |
1975年 | 25篇 |
1974年 | 29篇 |
1973年 | 41篇 |
1972年 | 30篇 |
1971年 | 29篇 |
1970年 | 27篇 |
1969年 | 27篇 |
1968年 | 23篇 |
1966年 | 22篇 |
排序方式: 共有4337条查询结果,搜索用时 19 毫秒
1.
2.
LGBQ+ individuals experience worse health outcomes than do other individuals. Some communication research finds that LGBQ+ individuals report receiving poor care during the mid- to post-health care, but this research assumes that LGBQ+ individuals have already received care. Little research has examined the pre- to early encounter experience of LGBQ+ individuals. This study presents exploratory research into how LGBQ+ individuals seek “queer-friendly” health care during pre- and early encounter experiences. Using an interview methodology, we report the facilitators and barriers to seeking queer-friendly care reported by LGBQ+ individuals. We offer implications for how health care providers and systems can better promote queer-friendly healthcare. 相似文献
3.
Sebastian Mondaca Walid K. Chatila David Bates Jaclyn F. Hechtman Andrea Cercek Neil H. Segal Zsofia K. Stadler Anna M. Varghese Ritika Kundra Marinela Capanu Jinru Shia Nikolaus Schultz Leonard Saltz Rona Yaeger 《Clinical colorectal cancer》2019,18(1):e39-e52
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献4.
5.
6.
The American public is increasingly concerned about risks associated with food additives like high-fructose corn syrup (HFCS). To promote its product as safe, the Corn Refiners Association (CRA) employed two forms of straw-person arguments. First, the CRA opportunistically misrepresented HFCS opposition as inept. Second, the CRA strategically chose to refute claims that were easier to defeat while remaining ambiguous about more complex points of contention. We argue that CRA’s discursive contributions represented unreasonable yet sustainable use of straw-person arguments in debates surrounding health and risk. 相似文献
7.
8.
9.
K. Molloy C. Jonak F.J.S.H. Woei-A-Jin E. Guenova A.M. Busschots A. Bervoets E. Hauben R. Knobler S. Porkert C. Fassnacht R. Cowan E. Papadavid M. Beylot-Barry E. Berti S. Alberti Violetti T. Estrach R. Matin O. Akilov L. Vakeva M. Prince A. Bates M. Bayne R. Wachsmuch U. Wehkamp M. Marschalko O. Servitje D. Turner S. Weatherhead M. Wobser J.A. Sanches P. McKay D. Klemke C. Peng A. Howles J. Yoo F. Evison J. Scarisbrick 《The British journal of dermatology》2020,182(3):770-779
10.
Psychiatric Quarterly - For centuries, attempting a successful rehabilitation of youth with antisocial behaviors has challenged juvenile justice systems and society. More recently, advances in... 相似文献